Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more
Market Cap & Net Worth: Dr. Reddy's Laboratories Limited (RDDA)
Dr. Reddy's Laboratories Limited (F:RDDA) has a market capitalization of $10.43 Billion (€10.16 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #2076 globally and #153 in its home market, demonstrating a 0.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dr. Reddy's Laboratories Limited's stock price €12.20 by its total outstanding shares 832523765 (832.52 Million).
Dr. Reddy's Laboratories Limited Market Cap History: 2015 to 2026
Dr. Reddy's Laboratories Limited's market capitalization history from 2015 to 2026. Data shows growth from $4.85 Billion to $10.43 Billion (4.80% CAGR).
Dr. Reddy's Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dr. Reddy's Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Dr. Reddy's Laboratories Limited's market cap is 0.03 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.18x
Dr. Reddy's Laboratories Limited's market cap is 0.18 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $3.69 Billion | $140.81 Billion | $12.04 Billion | 0.03x | 0.31x |
| 2018 | $4.11 Billion | $142.03 Billion | $9.81 Billion | 0.03x | 0.42x |
| 2019 | $4.75 Billion | $153.85 Billion | $18.80 Billion | 0.03x | 0.25x |
| 2020 | $7.73 Billion | $174.60 Billion | $19.50 Billion | 0.04x | 0.40x |
| 2021 | $8.17 Billion | $189.72 Billion | $19.15 Billion | 0.04x | 0.43x |
| 2022 | $7.31 Billion | $214.39 Billion | $23.57 Billion | 0.03x | 0.31x |
| 2023 | $10.18 Billion | $245.88 Billion | $45.07 Billion | 0.04x | 0.23x |
| 2024 | $12.82 Billion | $279.16 Billion | $55.68 Billion | 0.05x | 0.23x |
| 2025 | $10.08 Billion | $325.54 Billion | $56.54 Billion | 0.03x | 0.18x |
Competitor Companies of RDDA by Market Capitalization
Companies near Dr. Reddy's Laboratories Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Dr. Reddy's Laboratories Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Dr. Reddy's Laboratories Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Dr. Reddy's Laboratories Limited's market cap moved from $4.85 Billion to $ 10.43 Billion, with a yearly change of 4.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €10.43 Billion | +3.39% |
| 2025 | €10.08 Billion | -21.33% |
| 2024 | €12.82 Billion | +25.97% |
| 2023 | €10.18 Billion | +39.14% |
| 2022 | €7.31 Billion | -10.52% |
| 2021 | €8.17 Billion | +5.77% |
| 2020 | €7.73 Billion | +62.51% |
| 2019 | €4.75 Billion | +15.67% |
| 2018 | €4.11 Billion | +11.46% |
| 2017 | €3.69 Billion | -23.31% |
| 2016 | €4.81 Billion | -0.88% |
| 2015 | €4.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Dr. Reddy's Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.43 Billion USD |
| MoneyControl | $10.43 Billion USD |
| MarketWatch | $10.43 Billion USD |
| marketcap.company | $10.43 Billion USD |
| Reuters | $10.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.